These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Systematic Review and Meta-Analysis: Preoperative Vedolizumab Treatment and Postoperative Complications in Patients with Inflammatory Bowel Disease. Law CCY; Narula A; Lightner AL; McKenna NP; Colombel JF; Narula N J Crohns Colitis; 2018 Apr; 12(5):538-545. PubMed ID: 29718245 [TBL] [Abstract][Full Text] [Related]
5. Risk of postoperative infectious complications from medical therapies in inflammatory bowel disease. Law CC; Bell C; Koh D; Bao Y; Jairath V; Narula N Cochrane Database Syst Rev; 2020 Oct; 10(10):CD013256. PubMed ID: 33098570 [TBL] [Abstract][Full Text] [Related]
6. Preoperative use of anti-TNF therapy and postoperative complications in inflammatory bowel diseases: a meta-analysis. Billioud V; Ford AC; Tedesco ED; Colombel JF; Roblin X; Peyrin-Biroulet L J Crohns Colitis; 2013 Dec; 7(11):853-67. PubMed ID: 23523418 [TBL] [Abstract][Full Text] [Related]
7. Risk of Postoperative Complications Among Inflammatory Bowel Disease Patients Treated Preoperatively With Vedolizumab. Yamada A; Komaki Y; Patel N; Komaki F; Aelvoet AS; Tran AL; Pekow J; Dalal S; Cohen RD; Cannon L; Umanskiy K; Smith R; Hurst R; Hyman N; Rubin DT; Sakuraba A Am J Gastroenterol; 2017 Sep; 112(9):1423-1429. PubMed ID: 28719595 [TBL] [Abstract][Full Text] [Related]
8. Systematic review and meta-analysis: risks of postoperative complications with preoperative use of anti-tumor necrosis factor-alpha biologics in inflammatory bowel disease patients. Moosvi Z; Duong J; Bechtold ML; Nguyen DL Eur J Gastroenterol Hepatol; 2021 Jun; 33(6):799-816. PubMed ID: 33079779 [TBL] [Abstract][Full Text] [Related]
9. Association between vedolizumab and postoperative complications in IBD: a systematic review and meta-analysis. Guo D; Jiang K; Hong J; Zhang M; Shi Y; Zhou B Int J Colorectal Dis; 2021 Oct; 36(10):2081-2092. PubMed ID: 34467414 [TBL] [Abstract][Full Text] [Related]
10. Biologics and 30-Day Postoperative Complications After Abdominal Operations for Crohn's Disease: Are There Differences in the Safety Profiles? Lightner AL; McKenna NP; Alsughayer A; Harmsen WS; Taparra K; Parker ME; Raffals LE; Loftus EV Dis Colon Rectum; 2019 Nov; 62(11):1352-1362. PubMed ID: 31567927 [TBL] [Abstract][Full Text] [Related]
14. Evaluation of adverse clinical outcomes in patients with inflammatory bowel disease receiving different sequences of first- and second-line biologic treatments: findings from ROTARY. Krugliak Cleveland N; Ghosh S; Chastek B; Bancroft T; Candela N; Fan T; Umashankar K; Rubin DT BMC Gastroenterol; 2024 Sep; 24(1):314. PubMed ID: 39289603 [TBL] [Abstract][Full Text] [Related]
15. Case-matched Comparison of Postoperative Outcomes Following Surgery for Inflammatory Bowel Disease After Exposure to Vedolizumab vs Other Biologics. Novello M; Stocchi L; Steele SR; Holubar SD; Duraes LC; Kessler H; Shawki S; Hull LT J Crohns Colitis; 2020 Feb; 14(2):185-191. PubMed ID: 31328222 [TBL] [Abstract][Full Text] [Related]
16. Risk of postoperative complications among ulcerative colitis patients treated preoperatively with vedolizumab: a matched case-control study. Kim JY; Zaghiyan K; Lightner A; Fleshner P BMC Surg; 2020 Mar; 20(1):46. PubMed ID: 32138717 [TBL] [Abstract][Full Text] [Related]
17. Comparative Outcomes and Safety of Vedolizumab vs Tumor Necrosis Factor Antagonists for Older Adults With Inflammatory Bowel Diseases. Singh S; Iversen AT; Allin KH; Jess T JAMA Netw Open; 2022 Sep; 5(9):e2234200. PubMed ID: 36178685 [TBL] [Abstract][Full Text] [Related]
18. Perioperative Use of Vedolizumab is not Associated with Postoperative Infectious Complications in Patients with Ulcerative Colitis Undergoing Colectomy. Ferrante M; de Buck van Overstraeten A; Schils N; Moens A; Van Assche G; Wolthuis A; Vermeire S; D'Hoore A J Crohns Colitis; 2017 Oct; 11(11):1353-1361. PubMed ID: 28981886 [TBL] [Abstract][Full Text] [Related]
19. Postoperative complications of pediatric patients with inflammatory bowel disease treated with vedolizumab. Zimmerman LA; Zalieckas JM; Shamberger RC; Bousvaros A J Pediatr Surg; 2018 Jul; 53(7):1330-1333. PubMed ID: 29370898 [TBL] [Abstract][Full Text] [Related]